A phase II study of OGX-011 given prior to radical prostatectomy in patients with localized prostate cancer
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Antiandrogens; Custirsen
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Status changed from active, no longer recruiting to completed.
- 04 Oct 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.